- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01388647
Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast Cancer
Phase I/II Study of Neoadjuvant Carboplatin, Eribulin Mesylate and Trastuzumab (ECH) for Operable HER2 Positive Breast Cancer
This study will evaluate the safety and efficacy of eribulin in combination with carboplatin and trastuzumab in the neoadjuvant setting in subjects who are human epidermal growth factor receptor (HER)2 positive and are clinically stage IIA to IIIB.
The study regimen will be administered every 3 weeks for a total of 6 cycles followed by definitive surgery.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
During Phase I, the eribulin dose will be assigned upon study enrollment. The maximum tolerated dose (MTD) determined in Phase I will be the dose used for Phase II. Eribulin will be administered intravenously (IV) over 2 to 5 minutes on Days 1 and 8 of each cycle. Carboplatin area under the curve (AUC) 6 will be administered IV over 15 to 30 minutes on Day 1 of each cycle. Trastuzumab will be administered as an IV infusion on Day 1 of each cycle. A loading dose of 8 mg/kg of trastuzumab will be administered over 90 minutes on Cycle 1 Day 1. Then, a maintenance dose of 6 mg/kg of trastuzumab will be administered over 30 to 90 minutes on Day 1 of Cycles 2 - 6.
eribulin: During Phase I, the eribulin dose will be assigned upon study enrollment. The maximum tolerated dose (MTD) determined in Phase I will be the dose used for Phase II. Eribulin will be administered intravenously (IV) over 2 to 5 minutes on Days 1 and 8 of each cycle.
carboplatin: Carboplatin area under the curve
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Florida
-
Fort Lauderdale, Florida, United States, 33308
- Holy Cross Hospital
-
-
Georgia
-
Athens, Georgia, United States, 30607
- Northeast Georgia Cancer Care
-
Marietta, Georgia, United States, 30060
- Northwest Georgia Oncology Centers
-
-
Tennessee
-
Memphis, Tennessee, United States, 38120
- The West Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written informed consent
- Females; 18 years of age or greater
- Histologically proven invasive breast cancer
- American Joint Committee on Cancer (AJCC) clinical stage IIA - IIIB
- Tumor size greater than 10 millimeters
- HER2 positive
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Estrogen receptor (ER) positive or negative
- Ejection fraction greater than or equal to lower limit of normal for the institution by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA)
- Less than or equal to Grade 1 neuropathy according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
- Planned lumpectomy or mastectomy
- Eligible for radiation therapy
- No prior treatment for invasive breast cancer
- Adequate organ system function per protocol as determined within 7 days prior to first dose of study treatment
- Women of childbearing potential must have a negative pregnancy test within 7 days prior to the first dose of study treatment and must agree to use adequate contraception methods during study treatment and for a minimum of 6 months following trastuzumab discontinuation
- Female subjects who are lactating should discontinue nursing prior to the first dose of study treatment and should refrain from nursing throughout the treatment period
Exclusion Criteria:
- Fine needle cytology only without other histologic evidence of invasive breast cancer
- Inflammatory breast cancer
- AJCC clinical stage T1a-b breast cancer (primary tumor less than or equal to 10 millimeters)
- Evidence of metastatic disease
- HER2 negative
- Ejection fraction less than lower limit of normal for the institution by ECHO or MUGA
- Corrected QT interval greater than 480 milliseconds
- Pre-existing cardiac dysfunction
- Prior history of invasive cancer within the past 3 years
- Synchronous bilateral breast cancer
- Pre-existing CTCAE v4.0 Grade 2 or greater neuropathy
- Hypersensitivity to halichondrin B or halichondrin B chemical derivative
- History of severe allergic reactions to cisplatin or other platinum containing compounds, or mannitol
- Mild, moderate, or severe hepatic impairment
- Moderate or severe renal impairment
- Hypokalemia or hypomagnesemia if it cannot be corrected prior to the first dose of study treatment
- Organ allografts requiring immunosuppression
- Known positive human immunodeficiency virus (HIV) status
- Prior major surgery within 28 days prior to the first dose of study treatment and/or presence of any non-healing wound, fracture, or ulcer
- Minor surgery or radiation therapy within 14 days prior to the first dose of study treatment
- Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with subject's safety, provision of informed consent, or compliance to study procedures
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Eribulin, carboplatin, and trastuzumab
During Phase I, the eribulin dose will be assigned upon study enrollment.
The maximum tolerated dose (MTD) determined in Phase I will be the dose used for Phase II.
Eribulin will be administered intravenously (IV) over 2 to 5 minutes on Days 1 and 8 of each cycle.
Carboplatin area under the curve (AUC) 6 will be administered IV over 15 to 30 minutes on Day 1 of each cycle.
Trastuzumab will be administered as an IV infusion on Day 1 of each cycle.
A loading dose of 8 mg/kg of trastuzumab will be administered over 90 minutes on Cycle 1 Day 1.
Then, a maintenance dose of 6 mg/kg of trastuzumab will be administered over 30 to 90 minutes on Day 1 of Cycles 2 - 6.
|
During Phase I, the eribulin dose will be assigned upon study enrollment.
The maximum tolerated dose (MTD) determined in Phase I will be the dose used for Phase II.
Eribulin will be administered intravenously (IV) over 2 to 5 minutes on Days 1 and 8 of each cycle.
Other Names:
Carboplatin area under the curve (AUC) 6 will be administered IV over 15 to 30 minutes on Day 1 of each cycle.
Trastuzumab will be administered as an IV infusion on Day 1 of each cycle.
A loading dose of 8 mg/kg of trastuzumab will be administered over 90 minutes on Cycle 1 Day 1.
Then, a maintenance dose of 6 mg/kg of trastuzumab will be administered over 30 to 90 minutes on Day 1 of Cycles 2 - 6.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pathologic Response
Time Frame: Assessed at time of definitive surgery, approximately 21-26 weeks from study treatment start
|
Definitive surgery will be performed 3 to 8 weeks after completion of study treatment.
The pathology report will be scored for pathologic response: complete pathologic response (no invasive cancer in breast or lymph nodes; residual DCIS or LCIS is acceptable), partial pathologic response (residual invasive cancer in breast and/or lymph nodes), or no response (pathologic staging is equal to or worse than pretreatment clinical staging).
|
Assessed at time of definitive surgery, approximately 21-26 weeks from study treatment start
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical Response
Time Frame: Assessed prior to definitive surgery, approximately 18 weeks from study treatment start.
|
Clinical assessment of response will be performed 3 weeks after completion of study treatment.
The treating physician will assess clinical response using physical examination and radiologic evaluation.
Clinical response options are complete response (no invasive tumor in breast and lymph nodes), partial response (> 50% reduction in longest diameter of pretreatment tumor), no response (< 50% response to 10% growth of tumor as determined by longest diameter of pretreatment tumor size), and progression.
|
Assessed prior to definitive surgery, approximately 18 weeks from study treatment start.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Tolerated Dose (MTD) of Eribulin in Combination With Carboplatin and Trastuzuamb
Time Frame: Approximately 22 days from study treatment start, per subject
|
The MTD is defined as the dose at which <= 1 of 6 subjects experience DLT (Dose Limiting Toxicity) and above which >= 2 of 6 subjects experience DLT.
|
Approximately 22 days from study treatment start, per subject
|
Dose Limiting Toxicity (DLT)
Time Frame: Approximately 22 days from study treatment start, per subject
|
DLT is defined as grade 4 thrombocytopenia; grade 4 anemia; grade 4 neutropenia lasting > 5 days; or any grade 3 or 4 non-hematologic toxicity occurring during Cycle 1 which is attributable to eribulin, carboplatin, trastuzumab or the combination, or the inability to deliver all three agents at the assigned dose and scheduled time during Cycle 1.The following events are excluded from the DLT definition: grade 3 nausea and/or vomiting responsive to antiemetics; grade 3 fever or infection; grade 3 diarrhea responsive to antidiarrheal therapy.
|
Approximately 22 days from study treatment start, per subject
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Lee Schwartzberg, MD, FACP, Vector Oncology and The West Clinic
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ALSSNBC1006
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HER-2 Positive Breast Cancer
-
Memorial Sloan Kettering Cancer CenterNational Institutes of Health (NIH)RecruitingHER2-positive Metastatic Breast Cancer | HER-2 Protein Overexpression | HER-2 Positive Malignant Carcinoma of BreastUnited States
-
Orum Therapeutics USA, Inc.RecruitingHER2-positive Breast Cancer | HER-2 Gene Amplification | HER2 Gene Mutation | HER-2 Protein OverexpressionUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteTerminatedBreast Cancer | Breast Cancer, Male | HER2-positive Breast Cancer | HER-2 Gene Amplification | Breast Cancer Female | HER2 Positive Breast Carcinoma | HER-2 Protein OverexpressionUnited States
-
Alliance Foundation Trials, LLC.Pfizer; Syneos Health; UNICANCER; German Breast Group; SOLTI Breast Cancer Research... and other collaboratorsActive, not recruitingHER-2 Positive Breast Cancer | Estrogen Receptor Positive Breast CancerUnited States, Spain, France, Italy, Germany, Australia, Portugal, New Zealand
-
Eli Lilly and CompanyCompletedHER-2 Positive Breast Cancer | Hormone Receptor Positive Breast CancerSpain, United States, Korea, Republic of, Belgium, France, Germany, Italy, Australia, Argentina, Canada, United Kingdom, Mexico, Brazil, Greece
-
Texas Tech University Health Sciences Center, El...WithdrawnBreast Cancer | Metastatic Breast Cancer | HER-2 Positive Breast Cancer | ER Positive Breast Cancer
-
Zhimin ShaoRoche Pharma AGUnknownHER-2 Positive Breast CancerChina
-
Hospices Civils de LyonNot yet recruiting
-
Adrienne G. WaksEli Lilly and Company; Verastem, Inc.RecruitingBreast Cancer | Hormone Receptor-positive Breast Cancer | Hormone Receptor Positive HER-2 Negative Breast CancerUnited States
-
Washington University School of MedicineMolecular Templates, Inc.WithdrawnHER2-positive Solid Tumor | HER-2 Positive Cancer
Clinical Trials on eribulin
-
Zhejiang Cancer HospitalNot yet recruiting
-
Eisai LimitedCompleted
-
Spexis AGTerminatedMetastatic Breast Cancer | Locally Recurrent Breast CancerSpain, Belgium, United States, United Kingdom, Korea, Republic of, Taiwan, Italy, Russian Federation, Czechia, France, Brazil, Argentina, Ukraine
-
Eisai LimitedCompletedAdvanced Solid TumorFrance
-
Eisai GmbHCompletedLocally Advanced or Metastatic Breast CancerGermany
-
The First Affiliated Hospital with Nanjing Medical...Not yet recruitingTriple Negative Breast CancerChina
-
National Cancer Institute (NCI)CompletedHead and Neck CancerUnited States
-
Massachusetts General HospitalEisai Inc.Active, not recruitingAngiosarcoma | Epithelioid HemangioendotheliomaUnited States
-
Institut Cancerologie de l'OuestCompleted
-
Eisai Korea Inc.CompletedBreast Cancer | Breast NeoplasmsKorea, Republic of